InsiderTrades

Form 4 for KLRS Kalaris Therapeutics, Inc.

Accepted 2021-09-20 00:00:00 ET · period of report 2021-02-17 · accession 0000899243-21-036636 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2021-09-20 2021-02-17+ KLRS VAN BEEK JEROEN B Chief Commercial Off S - Sale $26.57 -53.1K 490.1K -10% -$1.41M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-03-02 S D 512 $37.93 472,522 D — — (F2) As previously reported, the reporting person sold 17,100 shares of Common Stock between February 17, 2021 and March 2, 2021.
2 Common Common Stock 2021-05-18 S D 15,201 $22.80 457,321 D — —
3 Common Common Stock 2021-06-03 S D 508 $22.87 456,813 D — —
4 Common Common Stock 2021-09-17 S D 5,916 $25.08 435,179 D — — (F4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
5 Common Common Stock 2021-09-02 S D 513 $19.86 441,095 D — —
6 Common Common Stock 2021-08-17 S D 15,205 $17.82 441,608 D — —
7 Common Common Stock 2021-02-17 S D 15,196 $39.65 490,134 D — —